| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Oncology-Clinical Diagnosis: Hematologic TumorsHematology Malignancy |
1 University of Pennsylvania, Philadelphia, Pennsylvania; 2 Fox Chase Cancer Center, Philadelphia, Pennsylvania
1432
Objectives: We correlated FDG-PET response with progression free survival (PFS) and overall survival (OS) of NHL subjects following RIT.
Methods: Subjects with FDG-PET within 3 months before and after RIT for lymphoma were included. A nuclear medicine physician blindly interpreted the PET studies. Treatment responses based on pre-RIT and post-RIT FDG-PET results were recorded in along with clinical follow-up (f/u).
Results: 23 subjects (M=13, F=10, median age 54) with FDG-PET who received either Zevalin (14) or Bexxar (9) RIT for NHL were included. Subtypes of NHL were as follows: 10 follicular, 8 diffuse large B-cell, 4 mantle cell, and 1 marginal zone lymphoma. FDG-PET based response of NHL to RIT was: 6 (26%) complete response (CR), 5 (22%) partial response (PR), 7 (30%) stable disease (SD), and 5 (22%) progressive disease (PD). Of 11 subjects who responded on PET, 7 (64%) had eventual clinical progression (mean PFS=14.9 mo, range=0–55.13mo), whereas mean PFS for non-responders was 6.96 mo (range=0-31.43mo). Eight (73%) of 11 PET responders were alive at last f/u, whereas only 4 (33%) of 12 PET non-responders were alive at last f/u (range of last f/u=2.83-59.80mo). OS was 39.5mo for PET responders and 16.8mo for PET non-responders. PET responders had statistically significant longer PFS and OS than PET non-responders (p=0.004 and p<0.0001, respectively, unpaired t test).
Conclusions: Response to RIT, as evaluated by FDG-PET, is significantly associated with PFS and OS in subjects with NHL.
Research Support: EAC acknowledges Jim and Frannie Maguire for their support.
| ||||||||||||||||||||||||||||||||||||||
